Valuation: MedinCell

Market Cap 911M 1.04B 841M 775M 1.46B 100B 1.49B 10.05B 3.95B 49.18B 3.92B 3.83B 169B P/E 2026 *
-60x
P/E 2027 * 476x
Enterprise Value 895M 1.02B 826M 761M 1.44B 98.65B 1.47B 9.87B 3.88B 48.31B 3.85B 3.76B 166B EV / Sales 2026
32.7x
EV / Sales 2027 * 20x
Free-Float
70.47%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 62 08/01/2003
Director of Finance/CFO 52 31/08/2023
Chief Tech/Sci/R&D Officer 67 08/05/2022
Director TitleAgeSince
Director/Board Member 62 08/01/2003
Chairman - 12/03/2024
Director/Board Member - 24/05/2016
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 1.04B
+0.85%-0.80%+52.79%+161.33% 1,051B
+1.23%-1.53%+54.58%+59.08% 609B
+0.04%+2.58%+34.47%+86.33% 450B
+0.78%-0.71%+29.28%+24.10% 330B
+1.41%+0.58%+35.44%+40.67% 284B
-0.27%-1.87%+22.34%+22.51% 263B
-1.76%+2.37%-20.43%-38.00% 223B
-1.42%+0.80%+24.27%+57.50% 198B
-1.48%+3.43%+24.08%+71.67% 167B
Average -0.06%+0.54%+28.54%+53.91% 397.23B
Weighted average by Cap. +0.37%+0.02%+37.51%+79.63%

Financials

2026 2027 *
Net sales 31.96M 36.57M 29.49M 27.18M 51.24M 3.52B 52.37M 352M 139M 1.72B 137M 134M 5.94B 44.78M 51.24M 41.32M 38.08M 71.78M 4.93B 73.38M 494M 194M 2.42B 192M 188M 8.32B
Net income -13.98M -16M -12.9M -11.89M -22.41M -1.54B -22.91M -154M -60.65M -755M -60.08M -58.76M -2.6B 786K 899K 725K 668K 1.26M 86.58M 1.29M 8.67M 3.41M 42.4M 3.38M 3.3M 146M
Net Debt -16.07M -18.39M -14.83M -13.67M -25.76M -1.77B -26.33M -177M -69.7M -867M -69.04M -67.53M -2.99B -14.87M -17.01M -13.72M -12.65M -23.83M -1.64B -24.36M -164M -64.49M -802M -63.89M -62.49M -2.76B
Logo MedinCell
MedinCell S.A. is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas, combining its proprietary BEPO® technology with active ingredients already known and marketed. The BEPO® technology allows the regular delivery of a drug at optimal therapeutic dose for several days, weeks or months from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. The first treatment based on BEPO® technology, intended for the treatment of schizophrenia, was approved by the FDA in April 2023, and is now distributed in the United States by Teva under the name UZEDY® (BEPO® technology is licensed to Teva under the name SteadyTeqTM). As of March 31, 2025, the company had a portfolio of 2 products in phase III clinical development and 3 products in preclinical development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
25.38EUR
Average target price
34.51EUR
Spread / Average Target
+35.98%

Quarterly revenue - Rate of surprise